Screening Men for Prostate and Colorectal Cancer in the United States: Does Practice Reflect the Evidence?

JAMA

Volumn 289, Issue 11, 2003, Pages 1414-1420

  Sirovich, Brenda E ^a   Schwartz, Lisa M ^a,b   Woloshin, Steven ^b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SIGMOIDOSCOPY; UNITED STATES; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BLOOD; COLORECTAL TUMOR; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROSTATE TUMOR; STATISTICS; UTILIZATION REVIEW;

ADULT; AGED; AGED, 80 AND OVER; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0037454282     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.11.1414     Document Type: Article

References (54)

1. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer Surveillance Series: interpreting trends in prostate cancer, part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
2. Brawer M. Prostate-specific antigen: current status. CA Cancer J Clin. 1999;49:264-281.
3. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55:791-795.
4. Donovan JL, Frankel SJ, Neal DE, Hamdy FC. Screening for prostate cancer in the UK: seems to be creeping in by the back door. BMJ. 2001;323;763-764.
5. Hahn DL. Lack of knowledge regarding prostate-specific antigen screening: is ignorance bliss? J Fam Pract. 1999;48:679-681.
6. Labrie F. Screening and early treatment of prostate cancer are accumulating strong evidence and support. Prostate. 2000;43:215-222.
7. Mettlin C. Public health impact of prostate cancer early detection. Prostate. 1997;31:71-73.
8. Barry MJ. Early detection and aggressive treatment of prostate cancer: groping in the dark. J Gen Intern Med. 2000;15:749-751.
9. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38:83-91.
10. Boer R, Schroder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction [letter]. Prostate. 1999;40:130-131.
11. Labrie F, Candas B. Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial. Prostate. 1999;40:132-134.
12. Alexander FE, Prescott RJ. Reply to Labrie et al: results of the mortality analysis of the Quebec randomized/controlled trial (RCT). Prostate. 1999;40:135-137.
13. Labrie F, Candas B. The Quebec study shows a 69% decrease in prostate cancer death [letter]. Prostate. 1999;40:137.
14. American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997;126:480-484.
15. US Preventive Services Task Force. Screening for prostate cancer. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:119-134.
16. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8-22.
17. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy, part I: early detection and diagnosis of prostate cancer. Urology. 2001;57:217-224.
18. Ransohoff DF, Sandler RS. Clinical practice: screening for colorectal cancer. N Engl J Med. 2002;346:40-44.
19. Eddy DM. Screening for colorectal cancer. Ann Intern Med. 1990;113:373-384.
20. US Preventive Services Task Force. Screening for colorectal cancer. In: Guide to Clinical Preventive Services 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:89-103.
21. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594-642.
22. Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:868-877.
23. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365-1371.
24. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467-1471.
25. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477.
26. Fowler FJ, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-532.
27. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653-657.
28. Müller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy: a case-control study of 32,702 veterans. Ann Intern Med. 1995;123:904-910.
29. Trends in screening for colorectal cancer-United States, 1997 and 1999. MMWR Morb Mortal Wkly Rep. 2001;50:162-166.
30. Hoffman RM, Papenfuss MR, Buller DB, Moon TE. Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med. 1996;12:277-281.
31. Voss JD, Schectman JM. Prostate cancer screening practices and beliefs: a longitudinal physician survey. J Gen Intern Med. 2001;16:831-837.
32. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Overview 2001. Atlanta, Ga: US Dept of Health and Human Services; 2002. Available at: http://www.cdc.gov/brfss/surveydata/2001/overview_01.rtf. Accessed October 28, 2002.
33. Centers for Disease Control and Prevention. 2001 Behavioral Risk Factor Surveillance System Summary Data Quality Report. Atlanta, Ga: US Dept of Health and Human Services; 2002.
34. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1999. Bethesda, Md: National Cancer Institute; 2002. Available at: http://seer.cancer.gov /csr/1973_1999/. Accessed May 25, 2002.
35. National Center for Health Statistics. NCHS definitions: an alphabetical listing of many terms used at NCHS: years of potential life lost. Available at: http://www.cdc.gov/nchs/datawh/nchsdefs /yearsofpotentiallifelost.htm. Accessed September 18, 2002.
36. Surveillance, Epidemiology, and End Results. SEER Incidence and US Mortality Statistics. Bethesda, Md: National Cancer Institute; 1999. Available at: http://seer.cancer.gov/canques/. Accessed September 18, 2002.
37. Population Estimates Program, Population Division. Annual Population Estimates by Age Group and Sex, Selected Years from 1990 to 2000. Washington, DC: US Census Bureau; 2001. Available at: http://eire.census.gov/popest/data/age.php. Accessed September 18, 2002.
38. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer. 1997;80:1830-1834.
39. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.
40. Farrell MH, Murphy MA, Schneider CE. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen. Eff Clin Pract. 2002;5:91-94.
41. Woloshin S, Schwartz LM. The US Postal Service and cancer screening: stamps of approval? N Engl J Med. 1999;340:884-887.
42. Hawley ST, Levin B, Vernon SW. Colorectal screening by primary care physicians in two medical care organizations. Cancer Detect Prev. 2001;25:309-318.
43. Schroy PC 3rd, Geller AC, Crosier Wood M, et al. Utilization of colorectal cancer screening tests: a 1997 survey of Massachusetts internists. Prev Med. 2001;33:381-391.
44. Pignone M, Harris R, Kinsinger L. Videotape-based decision aid for colon cancer screening: a randomized controlled trial. Ann Intern Med. 2000;133:761-769.
45. National Center for Health Statistics. National Health Interview Survey Data. Hyattsville, Md: Division of Health Interview Statistics, National Center for Health Statistics; 2000.
46. McGovern PG, Lurie N, Margolis KL, Slater JS. Accuracy of self-report of mammography and Pap smear in a low-income urban population. Am J Prev Med. 1998;14:201-208.
47. Suarez L, Goldman DA, Weiss NS. Validity of Pap smear and mammogram self-reports in a low-income Hispanic population. Am J Prev Med. 1995;11:94-98.
48. Whitman S, Lacey L, Ansell D, et al. Do chart reviews and interviews provide the same information about breast and cervical cancer screening? Int J Epidemiol 1993;22:393-397.
49. Bowman JA, Redman S, Dickinson JA, et al. The accuracy of Pap smear utilization self-report: a methodological consideration in cervical screening research. Health Serv Res. 1991;26:97-107.
50. Volk RJ, Cass AR. The accuracy of primary care patients' self-reports of prostate-specific antigen testing. Am J Prev Med. 2002;22:56-58.
51. Jordan TR, Price JH, King KA, et al. The validity of male patients' self-reports regarding prostate cancer screening. Prev Med. 1999;28:297-303.
52. Mandelson MT, LaCroix AZ, Anderson LA, et al. Comparison of self-reported fecal occult blood testing with automated laboratory records among older women in a health maintenance organization. Am J Epidemiol. 1999;150:617-621.
53. Baier M, Calonge N, Cutter G, et al. Validity of self-reported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev. 2000;9:229-232.
54. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89:1406-1422.